106 results
8-K
EX-99.1
LRMR
Larimar Therapeutics Inc
30 Sep 15
Zafgen Announces Transition of Board of Directors
12:00am
industry. Mr. Perez has a wealth of experience in guiding corporate strategy in the biotechnology industry, with a focus on drug development … to the strategy in Prader-Willi syndrome and hypothalamic injury-associated obesity and other complex metabolic disorders, and to the transition to an integrated
S-1
LRMR
Larimar Therapeutics Inc
18 Apr 14
IPO registration
12:00am
next amendment regarding your strategy for patient enrollment that includes a discussion of how you expect to find and enroll PWS patients and any … regarding the Company’s enrollment strategy. Please see revisions on page 89 of the Registration Statement. The Company further advises the Staff
8-K
EX-99.1
LRMR
Larimar Therapeutics Inc
9 May 19
Zafgen Reports First Quarter 2019 Operating and Financial Results
4:26pm
strategy, drug safety and benefit-risk management. Dr. Singhal is responsible for leading and overseeing research, clinical and manufacturing strategy
8-K
EX-99.1
LRMR
Larimar Therapeutics Inc
7 Nov 18
Zafgen Reports Third Quarter 2018 Operating and Financial Results
4:15pm
)
Erin Brubaker, Vice President of Commercial Strategy and Business Development, who brings 25 years of experience including global leadership roles … in New Product Planning, Portfolio Strategy, Alliance Management and Commercial while at GlaxoSmithKline (GSK)
Third Quarter 2018 Financial Results
UPLOAD
LRMR
Larimar Therapeutics Inc
24 Apr 20
Letter from SEC
12:00am
Zafgen, Inc.
April 24, 2020
Page 2
Chondrial's business; or (ii) remove the disclosure.
Chondrial's Strategy, page 160
3. We note your
8-K
EX-99.1
tr2zlu
14 Nov 23
Larimar Therapeutics Reports Third Quarter 2023 Operating and Financial Results
12:00am
8-K
EX-99.1
v72jj
11 Mar 19
Results of Operations and Financial Condition
4:12pm
CORRESP
zvuhaemw86s28vzk
27 Apr 20
Correspondence with SEC
12:00am
PRE 14A
775zc5tgbiresek6ml
12 Apr 24
Preliminary proxy
6:06am
10-K/A
rcj9oy 9unod
29 Apr 16
Annual report (amended)
12:00am
UPLOAD
hlex cefgqv84d2ldf
6 Apr 20
Letter from SEC
12:00am
CORRESP
wdp40qb
10 Apr 20
Correspondence with SEC
12:00am
8-K
EX-99.1
od2 xxxsog46v
11 Mar 24
Other Events
4:09pm
8-K
EX-99.1
3h3a xeyxxgpsab4znu
20 May 24
Larimar Therapeutics Announces FDA has Removed Partial Clinical Hold for Nomlabofusp Program in Friedreich’s Ataxia
4:08pm
8-K
EX-99.1
a3e3pqxz1slgxel
26 May 21
Larimar Therapeutics Reports FDA Clinical Hold on CTI-1601 and Termination of Recently Announced Private Placement Financing
10:17am
DEFA14A
scw 2dg36i
18 May 20
Additional proxy soliciting materials
9:55pm